{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T13:48:59Z","timestamp":1782827339539,"version":"3.54.5"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"publisher","award":["LY21H160003"],"award-info":[{"award-number":["LY21H160003"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"publisher","award":["LY13H160025"],"award-info":[{"award-number":["LY13H160025"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Gene Ther"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1038\/s41417-026-01009-8","type":"journal-article","created":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T08:10:59Z","timestamp":1771229459000},"page":"405-416","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["MSCs delivering LIGHT prime immune response against CAFs to harness antigen loss variants"],"prefix":"10.1038","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8559-6066","authenticated-orcid":false,"given":"Weibin","family":"Zou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5569-8703","authenticated-orcid":false,"given":"Linbing","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5241-847X","authenticated-orcid":false,"given":"Wei","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,16]]},"reference":[{"key":"1009_CR1","first-page":"3569","volume":"60","author":"RT Reilly","year":"2000","unstructured":"Reilly RT, Gottlieb MB, Ercolini AM, Machiels JP, Kane CE, Okoye FI, et al. HER-2\/neu is a tumor rejection target in tolerized HER-2\/neu transgenic mice. Cancer Res. 2000;60:3569\u201376.","journal-title":"Cancer Res"},{"key":"1009_CR2","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1002\/cam4.715","volume":"5","author":"M Morita","year":"2016","unstructured":"Morita M, Yamaguchi R, Tanaka M, Tse GM, Yamaguchi M, Kanomata N, et al. CD8(+) tumor-infiltrating lymphocytes contribute to spontaneous \u201chealing\u201d in HER2-positive ductal carcinoma in situ. Cancer Med. 2016;5:1607\u201318.","journal-title":"Cancer Med"},{"key":"1009_CR3","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/0046-8177(92)90257-4","volume":"23","author":"DC Allred","year":"1992","unstructured":"Allred DC, Clark GM, Molina R, Tandon AK, Schnitt SJ, Gilchrist KW, et al. Overexpression of HER-2\/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Hum Pathol. 1992;23:974\u20139.","journal-title":"Hum Pathol"},{"key":"1009_CR4","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1002\/eji.200636639","volume":"37","author":"M Kmieciak","year":"2007","unstructured":"Kmieciak M, Knutson KL, Dumur CI, Manjili MH. HER-2\/neu antigen loss and relapse of mammary carcinoma are actively induced by T cell-mediated anti-tumor immune responses. Eur J Immunol. 2007;37:675\u201385.","journal-title":"Eur J Immunol"},{"key":"1009_CR5","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.ccell.2018.01.011","volume":"33","author":"A Costa","year":"2018","unstructured":"Costa A, Kieffer Y, Scholer-Dahirel A, Pelon F, Bourachot B, Cardon M, et al. Fibroblast Heterogeneity and Immunosuppressive Environment in Human Breast Cancer. Cancer Cell. 2018;33:463\u201379.e10.","journal-title":"Cancer Cell"},{"key":"1009_CR6","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1038\/nrc.2016.73","volume":"16","author":"R Kalluri","year":"2016","unstructured":"Kalluri R. The biology and function of fibroblasts in cancer. Nat Rev Cancer. 2016;16:582\u201398.","journal-title":"Nat Rev Cancer"},{"key":"1009_CR7","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/s41586-022-05272-1","volume":"611","author":"AT Krishnamurty","year":"2022","unstructured":"Krishnamurty AT, Shyer JA, Thai M, Gandham V, Buechler MB, Yang YA, et al. LRRC15(+) myofibroblasts dictate the stromal setpoint to suppress tumour immunity. Nature. 2022;611:148\u201354.","journal-title":"Nature"},{"key":"1009_CR8","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1158\/2159-8290.CD-19-1384","volume":"10","author":"Y Kieffer","year":"2020","unstructured":"Kieffer Y, Hocine HR, Gentric G, Pelon F, Bernard C, Bourachot B, et al. Single-cell analysis reveals fibroblast clusters linked to immunotherapy resistance in cancer. Cancer Discov. 2020;10:1330\u201351.","journal-title":"Cancer Discov"},{"key":"1009_CR9","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abp9229","volume":"15","author":"I Melero","year":"2023","unstructured":"Melero I, Tanos T, Bustamante M, Sanmamed MF, Calvo E, Moreno I, et al. A first-in-human study of the fibroblast activation protein-targeted, 4-1BB agonist RO7122290 in patients with advanced solid tumors. Sci Transl Med. 2023;15:eabp9229.","journal-title":"Sci Transl Med"},{"key":"1009_CR10","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.semcancer.2022.09.002","volume":"86","author":"Z Tu","year":"2022","unstructured":"Tu Z, Karnoub AE. Mesenchymal stem\/stromal cells in breast cancer development and management. Semin Cancer Biol. 2022;86:81\u201392.","journal-title":"Semin Cancer Biol"},{"key":"1009_CR11","doi-asserted-by":"publisher","first-page":"3075","DOI":"10.1084\/jem.20180818","volume":"215","author":"Y Raz","year":"2018","unstructured":"Raz Y, Cohen N, Shani O, Bell RE, Novitskiy SV, Abramovitz L, et al. Bone marrow-derived fibroblasts are a functionally distinct stromal cell population in breast cancer. J Exp Med. 2018;215:3075\u201393.","journal-title":"J Exp Med"},{"key":"1009_CR12","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.ccr.2011.01.020","volume":"19","author":"M Quante","year":"2011","unstructured":"Quante M, Tu SP, Tomita H, Gonda T, Wang SS, Takashi S, et al. Bone marrow-derived myofibroblasts contribute to the mesenchymal stem cell niche and promote tumor growth. Cancer Cell. 2011;19:257\u201372.","journal-title":"Cancer Cell"},{"key":"1009_CR13","doi-asserted-by":"publisher","first-page":"8492","DOI":"10.1158\/0008-5472.CAN-04-1708","volume":"64","author":"NC Direkze","year":"2004","unstructured":"Direkze NC, Hodivala-Dilke K, Jeffery R, Hunt T, Poulsom R, Oukrif D, et al. Bone marrow contribution to tumor-associated myofibroblasts and fibroblasts. Cancer Res. 2004;64:8492\u20135.","journal-title":"Cancer Res"},{"key":"1009_CR14","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1093\/stmcls\/sxac036","volume":"40","author":"L Frisbie","year":"2022","unstructured":"Frisbie L, Buckanovich RJ, Coffman L. Carcinoma-associated mesenchymal stem\/stromal cells: architects of the pro-tumorigenic tumor microenvironment. Stem Cells. 2022;40:705\u201315.","journal-title":"Stem Cells"},{"key":"1009_CR15","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1158\/0008-5472.CAN-16-3507","volume":"78","author":"S Rossnagl","year":"2018","unstructured":"Rossnagl S, Ghura H, Groth C, Altrock E, Jakob F, Schott S, et al. A subpopulation of stromal cells controls cancer cell homing to the bone marrow. Cancer Res. 2018;78:129\u201342.","journal-title":"Cancer Res"},{"key":"1009_CR16","doi-asserted-by":"publisher","first-page":"2980","DOI":"10.1158\/0008-5472.CAN-11-4216","volume":"72","author":"W Zou","year":"2012","unstructured":"Zou W, Zheng H, He TC, Chang J, Fu YX, Fan W. LIGHT delivery to tumors by mesenchymal stem cells mobilizes an effective antitumor immune response. Cancer Res. 2012;72:2980\u20139.","journal-title":"Cancer Res"},{"key":"1009_CR17","doi-asserted-by":"publisher","first-page":"4134","DOI":"10.1158\/0008-5472.CAN-08-4698","volume":"69","author":"MR Loebinger","year":"2009","unstructured":"Loebinger MR, Eddaoudi A, Davies D, Janes SM. Mesenchymal stem cell delivery of TRAIL can eliminate metastatic cancer. Cancer Res. 2009;69:4134\u201342.","journal-title":"Cancer Res"},{"key":"1009_CR18","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1093\/jnci\/djh299","volume":"96","author":"M Studeny","year":"2004","unstructured":"Studeny M, Marini FC, Dembinski JL, Zompetta C, Cabreira-Hansen M, Bekele BN, et al. Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. J Natl Cancer Inst. 2004;96:1593\u2013603.","journal-title":"J Natl Cancer Inst"},{"key":"1009_CR19","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1158\/0008-5472.CAN-03-0173","volume":"64","author":"KL Knutson","year":"2004","unstructured":"Knutson KL, Almand B, Dang Y, Disis ML. Neu antigen-negative variants can be generated after neu-specific antibody therapy in neu transgenic mice. Cancer Res. 2004;64:1146\u201351.","journal-title":"Cancer Res"},{"key":"1009_CR20","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/nprot.2008.221","volume":"4","author":"M Soleimani","year":"2009","unstructured":"Soleimani M, Nadri S. A protocol for isolation and culture of mesenchymal stem cells from mouse bone marrow. Nat Protoc. 2009;4:102\u20136.","journal-title":"Nat Protoc"},{"key":"1009_CR21","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/s43018-022-00352-7","volume":"3","author":"L Liu","year":"2022","unstructured":"Liu L, Chen J, Zhang H, Ye J, Moore C, Lu C, et al. Concurrent delivery of immune checkpoint blockade modulates T cell dynamics to enhance neoantigen vaccine-generated antitumor immunity. Nat Cancer. 2022;3:437\u201352.","journal-title":"Nat Cancer"},{"key":"1009_CR22","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/ni1029","volume":"5","author":"P Yu","year":"2004","unstructured":"Yu P, Lee Y, Liu W, Chin RK, Wang J, Wang Y, et al. Priming of naive T cells inside tumors leads to eradication of established tumors. Nat Immunol. 2004;5:141\u20139.","journal-title":"Nat Immunol"},{"key":"1009_CR23","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.ccr.2010.06.014","volume":"18","author":"S Park","year":"2010","unstructured":"Park S, Jiang Z, Mortenson ED, Deng L, Radkevich-Brown O, Yang X, et al. The therapeutic effect of anti-HER2\/neu antibody depends on both innate and adaptive immunity. Cancer Cell. 2010;18:160\u201370.","journal-title":"Cancer Cell"},{"key":"1009_CR24","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/s41571-024-00924-9","volume":"21","author":"J Yoon","year":"2024","unstructured":"Yoon J, Oh DY. HER2-targeted therapies beyond breast cancer\u2014an update. Nat Rev Clin Oncol. 2024;21:675\u2013700.","journal-title":"Nat Rev Clin Oncol"},{"key":"1009_CR25","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.4049\/jimmunol.179.3.1960","volume":"179","author":"P Yu","year":"2007","unstructured":"Yu P, Lee Y, Wang Y, Liu X, Auh S, Gajewski TF, et al. Targeting the primary tumor to generate CTL for the effective eradication of spontaneous metastases. J Immunol. 2007;179:1960\u20138.","journal-title":"J Immunol"},{"key":"1009_CR26","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.cytogfr.2008.04.004","volume":"19","author":"P Yu","year":"2008","unstructured":"Yu P, Fu YX. Targeting tumors with LIGHT to generate metastasis-clearing immunity. Cytokine Growth Factor Rev. 2008;19:285\u201394.","journal-title":"Cytokine Growth Factor Rev"},{"key":"1009_CR27","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1158\/1078-0432.CCR-23-3841","volume":"30","author":"M Wehrli","year":"2024","unstructured":"Wehrli M, Guinn S, Birocchi F, Kuo A, Sun Y, Larson RC, et al. Mesothelin CAR T cells secreting anti-FAP\/Anti-CD3 molecules efficiently target pancreatic adenocarcinoma and its stroma. Clin Cancer Res. 2024;30:1859\u201377.","journal-title":"Clin Cancer Res"},{"key":"1009_CR28","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/mt.2008.229","volume":"17","author":"D Bexell","year":"2009","unstructured":"Bexell D, Gunnarsson S, Tormin A, Darabi A, Gisselsson D, Roybon L, et al. Bone marrow multipotent mesenchymal stroma cells act as pericyte-like migratory vehicles in experimental gliomas. Mol Ther. 2009;17:183\u201390.","journal-title":"Mol Ther"},{"key":"1009_CR29","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1517\/14712598.2010.517191","volume":"10","author":"J Feng","year":"2010","unstructured":"Feng J, Mantesso A, Sharpe PT. Perivascular cells as mesenchymal stem cells. Expert Opin Biol Ther. 2010;10:1441\u201351.","journal-title":"Expert Opin Biol Ther"},{"key":"1009_CR30","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/s41575-020-0300-1","volume":"17","author":"AN Hosein","year":"2020","unstructured":"Hosein AN, Brekken RA, Maitra A. Pancreatic cancer stroma: an update on therapeutic targeting strategies. Nat Rev Gastroenterol Hepatol. 2020;17:487\u2013505.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1009_CR31","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1084\/jem.20062056","volume":"204","author":"B Zhang","year":"2007","unstructured":"Zhang B, Bowerman NA, Salama JK, Schmidt H, Spiotto MT, Schietinger A, et al. Induced sensitization of tumor stroma leads to eradication of established cancer by T cells. J Exp Med. 2007;204:49\u201355.","journal-title":"J Exp Med"},{"key":"1009_CR32","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1084\/jem.193.11.1327","volume":"193","author":"Q Wu","year":"2001","unstructured":"Wu Q, Salomon B, Chen M, Wang Y, Hoffman LM, Bluestone JA, et al. Reversal of spontaneous autoimmune insulitis in nonobese diabetic mice by soluble lymphotoxin receptor. J Exp Med. 2001;193:1327\u201332.","journal-title":"J Exp Med"},{"key":"1009_CR33","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1172\/JCI200113827","volume":"108","author":"J Wang","year":"2001","unstructured":"Wang J, Lo JC, Foster A, Yu P, Chen HM, Wang Y, et al. The regulation of T cell homeostasis and autoimmunity by T cell-derived LIGHT. J Clin Invest. 2001;108:1771\u201380.","journal-title":"J Clin Invest"},{"key":"1009_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-51867-9","volume":"15","author":"M Uhrbom","year":"2024","unstructured":"Uhrbom M, Muhl L, Genove G, Liu J, Palmgren H, Alexandersson I, et al. Adipose stem cells are sexually dimorphic cells with dual roles as preadipocytes and resident fibroblasts. Nat Commun. 2024;15:7643.","journal-title":"Nat Commun"},{"key":"1009_CR35","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1078\/0065-1281-00567","volume":"102","author":"F Jeney","year":"2000","unstructured":"Jeney F, Bazso-Dombi E, Oravecz K, Szabo J, Nagy IZ. Cytochemical studies on the fibroblast-preadipocyte relationships in cultured fibroblast cell lines. Acta Histochem. 2000;102:381\u20139.","journal-title":"Acta Histochem"},{"key":"1009_CR36","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1038\/s41591-019-0522-3","volume":"25","author":"KE Yost","year":"2019","unstructured":"Yost KE, Satpathy AT, Wells DK, Qi Y, Wang C, Kageyama R, et al. Clonal replacement of tumor-specific T cells following PD-1 blockade. Nat Med. 2019;25:1251\u20139.","journal-title":"Nat Med"}],"container-title":["Cancer Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41417-026-01009-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41417-026-01009-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41417-026-01009-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T13:28:25Z","timestamp":1782826105000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41417-026-01009-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,16]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["1009"],"URL":"https:\/\/doi.org\/10.1038\/s41417-026-01009-8","relation":{},"ISSN":["0929-1903","1476-5500"],"issn-type":[{"value":"0929-1903","type":"print"},{"value":"1476-5500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,16]]},"assertion":[{"value":"26 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Ethical approval was obtained from the Ethical Committee of Animal Research of Zhejiang Cancer hospital. All animal procedures were approved by the Institutional Animal Care and Use Committee of Zhejiang Cancer Hospital and conducted in strict compliance with China\u2019s National Guidelines for Laboratory Animal Welfare. This study did not involve human participants or human tissues. Therefore, informed consent was not required for this research.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}